Trial Profile
A Phase III, Multicenter, Randomized, Double-Blind, Active-Comparator Controlled Clinical Trial to Study the Safety and Efficacy of the Addition of Sitagliptin Compared with the Addition of Dapagliflozin in Subjects with Type 2 Diabetes Mellitus and Mild Renal Impairment Who Have Inadequate Glycemic Control on Metformin With or Without a Sulfonylurea
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 12 May 2022
Price :
$35
*
At a glance
- Drugs Sitagliptin (Primary) ; Dapagliflozin; Metformin; Sulfonylureas
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms CompoSIT-R
- Sponsors Merck Sharp & Dohme
- 11 Jun 2019 Results of a post hoc analysis of the cohort of patients ≥65 years, presented at the 79th Annual Scientific Sessions of the American Diabetes Association
- 05 Oct 2018 Results presented at the 54th Annual Meeting of the European Association for the Study of Diabetes
- 26 Jun 2018 Primary endpoint (Change from Baseline in A1C at Week 24) has been met.